Mircera approved for anemia in pediatric patients with CKD

Print Friendly, PDF & Email


Red blood cells
Mircera®, methoxy polyethylene glycol-epoetin beta, was approved by the US Food and Drug Administration (FDA) to treat anemia in pediatric patients who have chronic kidney disease (CKD). The drug is indicated for patients ages 5 to 17 years on hemodialysis who are switching from another erythropoiesis-stimulating agent (ESA) after their hemoglobin levels... [Read Article]
Print Friendly, PDF & Email

FDA approves first biosimilar pegfilgrastim

Print Friendly, PDF & Email


Vials and a syringe
The US Food and Drug Association (FDA) has approved pegfilgrastim-jmdb (Fulphila™) as the first biosimilar to Neulasta®. The agents reduce the risk of infection or the duration of febrile neutropenia in patients treated with immunosuppressive chemotherapy for non-myeloid hematologic malignancies. The FDA approved Fulphila based on evidence that included extensive... [Read Article]
Print Friendly, PDF & Email

Eltrombopag receives priority review designation for SAA

Print Friendly, PDF & Email


Eltrombopag (Promacta)
Photo courtesy of GSK
Eltrombopag (Promacta®) in combination with standard immunosuppressive therapy (IST) has received priority review designation from the US Food and Drug Administration (FDA) for first-line treatment of severe aplastic anemia (SAA). The drug is already approved for SAA in the refractory setting for patients who have had an insufficient... [Read Article]
Print Friendly, PDF & Email

FDA approves first epoetin alfa biosimilar

Print Friendly, PDF & Email


Red blood cells
The US Food and Drug Administration (FDA) has approved epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen/Procrit). Epoetin alfa-epbx is approved for the treatment of anemia caused by chronic kidney disease, the use of zidovudine in patients with HIV infection, and myelosuppressive chemotherapy in patients who have a minimum of... [Read Article]
Print Friendly, PDF & Email

Haplo-HSCT regimen can cure SCD, team says

Print Friendly, PDF & Email


Damiano Rondelli, MD
Photo from University
of Illinois at Chicago/
Jenny Fontaine
A haploidentical transplant regimen has led to long-term engraftment in adults with sickle cell disease (SCD), according to researchers. Seven of 8 patients treated with this regimen were still alive at last follow-up, and 6 of them maintained engraftment. Two patients developed... [Read Article]
Print Friendly, PDF & Email

Art education benefits blood cancer patients

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of CDC
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant. The BVAI involved an educator teaching patients art technique one-on-one for approximately 30 minutes. After a single session, patients had significant improvements in... [Read Article]
Print Friendly, PDF & Email

Drug shows promise for treating AML, MDS

Print Friendly, PDF & Email


Lab mouse
Preclinical results support clinical testing of an experimental agent in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to researchers. The agent, ALRN-6924, was shown to combat AML and MDS by restoring activity of the tumor-suppressing protein p53. ALRN-6924 exhibited antileukemic activity in AML cells and mouse models of the disease, as... [Read Article]
Print Friendly, PDF & Email